Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

Journal of Surgical Oncology

Volumn 99, Issue 1, 2009, Pages 42-47

  Eisenberg, Burton L ^a   Harris, Jonathan ^b   Blanke, Charles D ^c   Demetri, George D ^d   Heinrich, Michael C ^e   Watson, James C ^f   Hoffman, John P ^f   Okuno, Scott ^g   Kane, John M ^h   Von Mehren, Margaret ^f  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b AMERICAN COLLEGE OF RADIOLOGY   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g MAYO CLINIC   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

GIST; Locally advanced GIST; Metastatic GIST; Neoadjuvant imatinib

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABDOMINAL ABSCESS; ADJUVANT THERAPY; AMYLASE BLOOD LEVEL; ANOREXIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLITIS; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL STROMAL TUMOR; HEART DISEASE; HEART EDEMA; HUMAN; HYPOCALCEMIA; HYPONATREMIA; HYPOXIA; INFECTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; THROMBOSIS; TRACHEOESOPHAGEAL FISTULA; VOMITING; WOUND INFECTION; ADULT; AGED; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 58149399145     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21160     Document Type: Article

References (28)

1. Sanders L, Silverman M, Rossi R, et al.: Gastric smooth muscle tumors; diagnostic dilemmas and factors affecting outcome. World J Surg 1996;20:992-995.
2. Dematteo R, Lewis J, Leung D, et al.: Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58.
3. Ng E, Pollock R, Munsell M, et al.: Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and strategy. Ann Surg 1992;215:68-77.
4. Demetri G, von Mehren M, Blanke C, et al.: Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumors. N Eng J Med 2002;347:472-480.
5. DeMatteo R: ASCO 2007, abstract 10079.
6. Kalbfleisch JD, Prentice RL: The statistical analysis of failure time data. New York: John Wiley and Sons; 1980.
7. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.
8. Therasse P, Arbuck S, Eisenhauer E, et al.: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
9. Verweij P, Casali P, Zalcberg P, et al.: Progression-free survival in gastrointestinal stromal tumors with high dose Imatinib: Randomized trial. Lancet 2004;364:1127-1134.
10. Benjamin R, Rankin C, Fletcher C, et al.: Phase III dose-randomized study of Imatinib Mesylate for GIST: Intergroup S0033 early results [Abstract 3271]. Proc Am Soc Clin Oncol 2003;22:814.
11. Gold J, Dematteo R: Combined surgical and molecular therapy. The gastrointestinal stromal tumor model. Ann Surg 2006;244:176-184.
12. Haller F, Detken S, Hans-Jurgen S, et al.: Surgical management after neoadjuvant Imatinib therapy in gastrointestinal stromal tumors (GISTs) with respect to Imatinib resistence caused by secondary KIT mutations. Ann Surg Oncol 2007;14:526-531.
13. Bumming P, Andersson J, Meis-Kindblom J, et al.: Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumors (GIST) with Imatinib, a centre-based study of 17 patients. Br J Cancer 2003;89:460-464.
14. Liu C, Huang M, Lin S, et al.: Neoadjuvant STI571 therapy for high-risk gastrointestinal stromal tumor. Ann J Surg 2004;74:289-290.
15. Benjamin R, Choi H, Macapinlac H, et al.:We should decist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-1764.
16. Ng E, Pollock R, Romsdahl M: Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992;69:1334-1341.
17. Lo S, Papachristou G, Finkelstein S, et al.: Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: A report of a case. Dis Colon Rectum 2005;48:1316-1319.
18. Eisenberg B: Combining Imatinib with surgery in gastrointestinal stromal tumors: Rationale and on-going trials. Cin Colorectal Cancer 2006;6:S24-S29.
19. Andtbacka R, Ng C, Scaife C, et al.: Surgical resection of gastrointestinal stromal tumors after treatment with Imatinib. Ann Surg Oncol 2007;14:14-24.
20. Gronchi A, Fiore M, Miselli F, et al.: Surgery of residual disease following molecular-targeted therapy with Imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007;245:341-346.
21. Dematteo R: Efficacy of adjuvant Imatinib mesylate following complete resection of localized primary GIST at high risk of recurrence. The US Intergroup phase II trial ASOSOG Z9000. Abstract 8, presented at ASCO-GI 2008.
22. Dematteo R, Maki R, Singer S, et al.: Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007;245:347-352.
23. Rutkowski P, Nowecki Z, Nyckowski P, et al.: Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with Imatinib Mesylate. J Surg Oncol 2006;93:304-311.
24. Raut C, Posner M, Desai J, et al.: Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24:2325-2331.
25. Bauer S, Hartmann J, Dewitt M, et al.: Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with Imatinib. Int J Cancer 2005;117:316-325.
26. Blanke C, Demetri G, von Mehren M, et al.: Long term results from a randomized phase II trial of standard-versus higher dose Imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-625.
27. Roberts P, Eisenberg B: Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002;38:S37-S38.
28. Blay J, Cesne A, Ray-Coquard I, et al.: Prospective multi-centere randomized phase III study of Imatinib in patients with advanced gastrointestinal stromal tumors comparing interception versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 2007;25:1107-1113.